Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Epidemiological changes in Chlamydia pneumoniae molecular detections before, during and after the COVID-19 pandemic in 27 European sites and Taiwan, 2018 to 2023

F. Tagini, SA. Uldum, C. Berengua, B. Ivan, R. Capaul, S. Edouard, A. Fischer, J. Flipse, D. García Martínez de Artola, D. Goldenberger, E. Heddema, M. Hermans, F. Imkamp, D. Keše, C. Lejarraga, R. Lienhard, C. Maffioli, V. Matheeussen, PM. Meyer...

. 2025 ; 30 (23) : . [pub] -

Jazyk angličtina Země Švédsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015401

BackgroundDuring the COVID-19 pandemic, non-pharmaceutical interventions (NPIs) such as social distancing, lockdowns and enhanced hygiene led to a decrease in respiratory pathogens. However, as NPIs were relaxed, a resurgence in several respiratory pathogens was observed including one local Chlamydia pneumoniae outbreak in Switzerland, prompting the need for a better understanding of C. pneumoniae epidemiology.AimTo assess temporal and geographical variations in C. pneumoniae detection before, during and after the COVID-19 pandemic.MethodsData on C. pneumoniae PCR detection ratios (number of positive tests/ total number of tests) across pre-pandemic (2018-2019), pandemic (2020-2022) and post-pandemic (2023) periods were collected via a global survey disseminated through various professional networks.ResultsC. pneumoniae detection ratios were analysed across 28 sites (27 in Europe, one in Taiwan) in 2023 (Dataset A, n = 172,223 tests) and 20 sites from 2018 to 2023 (Dataset B, n = 693,106 tests). Twenty-seven sites were laboratories (hospital or clinical) and one a surveillance system (Denmark). A significant decrease in detection ratios was observed during the pandemic period (from 1.05% to 0.23%, p < 0.001). In 2023, detection ratios increased to 0.28% (p < 0.002). Notable regional variations were found, with statistically significant increases in detection ratios at six sites located in Switzerland and Slovenia, where ratios ranged from 0.52% to 3.25%.DiscussionThe study highlights how NPIs influenced C. pneumoniae epidemiology, with reduced detection during the pandemic and partial resurgence afterwards. Regional variations suggest differing NPI impacts and underscore the need for continued surveillance.

ADMED Microbiologie La Chaux de Fonds Switzerland

Bacteriology Laboratory Division of Laboratory Medicine Department of Diagnostics Geneva University Hospitals Geneva Switzerland

Department of Bacteria Parasites and Fungi Statens Serum Institut Copenhagen Denmark

Department of Bacteriology Bordeaux University Hospital Bordeaux France

Hospital Universitario Nuestra Señora de Candelaria Santa Cruz de Tenerife Spain

IHU Méditerranée Infection Marseille France

Infectious Diseases and Hospital Epidemiology University Children's Hospital Zurich Zurich Switzerland

Institute of Microbiology Lausanne University Hospital Lausanne Switzerland

Jeroen Bosch Hospital s Hertogenbosch the Netherlands

Laboratory Dr Risch Buchs Switzerland

Laboratory for diagnostics of atypical bacterial infections Institute of Microbiology and Immunology Faculty of Medicine Ljubljana Slovenia

Laboratory for Medical Microbiology and Immunology Rijnstate Hospital Arnhem the Netherlands

Luzerner Kantonsspital Lucerne Switzerland

MCL Laboratories Niederwangen Switzerland

MEDISYN SA Lucerne Switzerland

Microbiology Department Hospital de la Santa Creu i Sant Pau Barcelona Spain

Microbiology laboratory HUC Bilbao Spain

Motol University Hospital Prague Czechia

Star shl Rotterdam the Netherlands

Taichung Veterans General Hospital Taichung Taiwan

University Hospital Antwerp Antwerp Belgium

University Hospital Basel Basel Switzerland

University of Helsinki and Helsinki University Hospital Helsinki Finland

University of Zurich Institute of Medical Microbiology Zürich Switzerland

Zentrallabor Kantonspital Graubünden Chur Switzerland

Zuyderland Medical Centre Glims Sittard Geleen the Netherlands

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015401
003      
CZ-PrNML
005      
20250731090945.0
007      
ta
008      
250708s2025 sw f 000 0|eng||
009      
AR
024    7_
$a 10.2807/1560-7917.ES.2025.30.23.2400682 $2 doi
035    __
$a (PubMed)40511472
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sw
100    1_
$a Tagini, Florian $u Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland
245    10
$a Epidemiological changes in Chlamydia pneumoniae molecular detections before, during and after the COVID-19 pandemic in 27 European sites and Taiwan, 2018 to 2023 / $c F. Tagini, SA. Uldum, C. Berengua, B. Ivan, R. Capaul, S. Edouard, A. Fischer, J. Flipse, D. García Martínez de Artola, D. Goldenberger, E. Heddema, M. Hermans, F. Imkamp, D. Keše, C. Lejarraga, R. Lienhard, C. Maffioli, V. Matheeussen, PM. Meyer Sauteur, I. Mitrovic, O. Opota, C. Orasch, P. Drevinek, O. Peuchant, L. Po-Yu, M. Puolakkainen, M. Remy, KT. Thai, N. Wohlwend, G. Greub, ESCMID Study Group for Mycoplasma and Chlamydia infections (ESGMAC)
520    9_
$a BackgroundDuring the COVID-19 pandemic, non-pharmaceutical interventions (NPIs) such as social distancing, lockdowns and enhanced hygiene led to a decrease in respiratory pathogens. However, as NPIs were relaxed, a resurgence in several respiratory pathogens was observed including one local Chlamydia pneumoniae outbreak in Switzerland, prompting the need for a better understanding of C. pneumoniae epidemiology.AimTo assess temporal and geographical variations in C. pneumoniae detection before, during and after the COVID-19 pandemic.MethodsData on C. pneumoniae PCR detection ratios (number of positive tests/ total number of tests) across pre-pandemic (2018-2019), pandemic (2020-2022) and post-pandemic (2023) periods were collected via a global survey disseminated through various professional networks.ResultsC. pneumoniae detection ratios were analysed across 28 sites (27 in Europe, one in Taiwan) in 2023 (Dataset A, n = 172,223 tests) and 20 sites from 2018 to 2023 (Dataset B, n = 693,106 tests). Twenty-seven sites were laboratories (hospital or clinical) and one a surveillance system (Denmark). A significant decrease in detection ratios was observed during the pandemic period (from 1.05% to 0.23%, p < 0.001). In 2023, detection ratios increased to 0.28% (p < 0.002). Notable regional variations were found, with statistically significant increases in detection ratios at six sites located in Switzerland and Slovenia, where ratios ranged from 0.52% to 3.25%.DiscussionThe study highlights how NPIs influenced C. pneumoniae epidemiology, with reduced detection during the pandemic and partial resurgence afterwards. Regional variations suggest differing NPI impacts and underscore the need for continued surveillance.
650    _2
$a lidé $7 D006801
650    12
$a Chlamydophila pneumoniae $x izolace a purifikace $x genetika $7 D016993
650    12
$a COVID-19 $x epidemiologie $7 D000086382
650    _2
$a SARS-CoV-2 $7 D000086402
650    12
$a infekce bakteriemi rodu Chlamydophila $x epidemiologie $x diagnóza $7 D023521
650    _2
$a pandemie $7 D058873
650    _2
$a polymerázová řetězová reakce $7 D016133
651    _2
$a Evropa $x epidemiologie $7 D005060
651    _2
$a Taiwan $x epidemiologie $7 D013624
655    _2
$a časopisecké články $7 D016428
700    1_
$a Uldum, Søren Anker $u Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark
700    1_
$a Berengua, Carla $u Microbiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
700    1_
$a Ivan, Branislav $u University Hospital Basel, Basel, Switzerland
700    1_
$a Capaul, Riccarda $u Zentrallabor, Kantonspital Graubünden, Chur, Switzerland
700    1_
$a Edouard, Sophie $u IHU-Méditerranée Infection, Marseille, France
700    1_
$a Fischer, Adrien $u Bacteriology Laboratory, Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland
700    1_
$a Flipse, Jacky $u Laboratory for Medical Microbiology and Immunology, Rijnstate Hospital, Arnhem, the Netherlands
700    1_
$a García Martínez de Artola, Diego $u Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
700    1_
$a Goldenberger, Daniel $u University Hospital Basel, Basel, Switzerland
700    1_
$a Heddema, Edou $u Zuyderland Medical Centre, Glims, Sittard-Geleen, the Netherlands
700    1_
$a Hermans, Mirjam $u Jeroen Bosch Hospital, s-Hertogenbosch, the Netherlands
700    1_
$a Imkamp, Frank $u University of Zurich, Institute of Medical Microbiology, Zürich, Switzerland
700    1_
$a Keše, Darja $u Laboratory for diagnostics of atypical bacterial infections, Institute of Microbiology and Immunology, Faculty of Medicine, Ljubljana, Slovenia
700    1_
$a Lejarraga, Clara $u Microbiology laboratory, HUC, Bilbao, Spain
700    1_
$a Lienhard, Reto $u ADMED Microbiologie, La Chaux-de-Fonds, Switzerland
700    1_
$a Maffioli, Carola $u MCL Laboratories, Niederwangen, Switzerland
700    1_
$a Matheeussen, Veerle $u University Hospital Antwerp, Antwerp, Belgium
700    1_
$a Meyer Sauteur, Patrick M $u Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland
700    1_
$a Mitrovic, Irena $u Luzerner Kantonsspital, Lucerne, Switzerland
700    1_
$a Opota, Onya $u Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland
700    1_
$a Orasch, Christina $u MEDISYN SA, Lucerne, Switzerland
700    1_
$a Drevinek, Pavel $u Motol University Hospital, Prague, Czechia
700    1_
$a Peuchant, Olivia $u Department of Bacteriology, Bordeaux University Hospital, Bordeaux, France
700    1_
$a Po-Yu, Liu $u Taichung Veterans General Hospital, Taichung, Taiwan
700    1_
$a Puolakkainen, Mirja $u University of Helsinki and Helsinki University Hospital, Helsinki, Finland
700    1_
$a Remy, Melissa $u MEDISYN SA, Lucerne, Switzerland
700    1_
$a Thai, Khoa Td $u Star-shl, Rotterdam, the Netherlands
700    1_
$a Wohlwend, Nadia $u Laboratory Dr. Risch, Buchs, Switzerland
700    1_
$a Greub, Gilbert $u Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland
710    2_
$a ESCMID Study Group for Mycoplasma and Chlamydia infections (ESGMAC)
773    0_
$w MED00174364 $t Euro surveillance $x 1560-7917 $g Roč. 30, č. 23 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40511472 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090940 $b ABA008
999    __
$a ok $b bmc $g 2366313 $s 1252526
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 30 $c 23 $e - $i 1560-7917 $m Euro surveillance $n Euro Surveill $x MED00174364
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace